This is a multicenter, open-label, single-arm, phase II cilinical trial designed to evaluate the efficacy and safety of the KRAS G12C selective inhibitor HRS-7058 in patients with KRAS G12C-mutated advanced pancreatic cancer who had failed 1-2 lines of previous systemic therapy.
Informed consent was obtained from all participants before participating in the study.
Age from 18 to 75 years old (including both ends), regardless of gender;
Patients with locally advanced unresectable, recurrent unresectable or metastatic pancreatic cancer, and adenocarcinoma confirmed by cytology or histological pathology;
Participants had received at least one previous systemic therapy
Presence of untreated or active central nervous system (CNS) metastases. Participants with a history of leptomeningeal metastasis or current leptomeningeal metastasis, brainstem metastasis, spinal cord metastasis, and/or spinal cord compression.
Subjects who had received general anesthesia
Subjects with a history of myocardial infarction or unstable angina pectoris
Subjects with atrioventricular block or cardiac insufficiency